CIBC Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.4M Sell
136,785
-3,169
-2% -$265K 0.03% 363
2026
Q1
$11.2M Buy
139,954
+2,136
+2% +$176K 0.03% 351
2025
Q4
$11.7M Buy
137,818
+54,985
+66% +$4.51M 0.03% 339
2025
Q3
$6.44M Sell
82,833
-190
-0.2% -$14.8K 0.02% 374
2025
Q2
$6.49M Sell
83,023
-7,689
-8% -$573K 0.02% 373
2025
Q1
$6.57M Sell
90,712
-2,715
-3% -$194K 0.02% 365
2024
Q4
$6.92M Sell
93,427
-31,973
-25% -$2.24M 0.02% 355
2024
Q3
$8.28M Buy
125,400
+7,749
+7% +$563K 0.03% 315
2024
Q2
$10.9M Sell
117,651
-3,874
-3% -$343K 0.04% 249
2024
Q1
$11.6M Buy
121,525
+6,550
+6% +$550K 0.04% 247
2023
Q4
$8.77M Buy
114,975
+27,324
+31% +$1.9M 0.03% 278
2023
Q3
$6.07M Sell
87,651
-2,357
-3% -$189K 0.03% 324
2023
Q2
$8.49M Sell
90,008
-1,114
-1% -$96.8K 0.03% 273
2023
Q1
$7.54M Buy
91,122
+1,417
+2% +$111K 0.03% 291
2022
Q4
$6.69M Buy
89,705
+5,689
+7% +$438K 0.03% 304
2022
Q3
$6.94M Buy
84,016
+6,862
+9% +$660K 0.03% 276
2022
Q2
$7.34M Buy
77,154
+16,410
+27% +$1.7M 0.03% 259
2022
Q1
$7.15M Buy
60,744
+634
+1% +$71.1K 0.03% 296
2021
Q4
$7.79M Buy
60,110
+3,063
+5% +$357K 0.03% 296
2021
Q3
$6.46M Buy
57,047
+1,635
+3% +$187K 0.03% 306
2021
Q2
$5.74M Buy
55,412
+570
+1% +$53.7K 0.02% 327
2021
Q1
$4.59M Sell
54,842
-613
-1% -$51.8K 0.02% 341
2020
Q4
$5.06M Sell
55,455
-79
-0.1% -$6.55K 0.02% 310
2020
Q3
$4.43M Buy
55,534
+1,008
+2% +$78.7K 0.02% 296
2020
Q2
$3.77M Buy
54,526
+250
+0.5% +$17.8K 0.02% 296
2020
Q1
$3.41M Sell
54,276
-1,569
-3% -$113K 0.02% 290
2019
Q4
$4.34M Sell
55,845
-5,508
-9% -$430K 0.02% 282
2019
Q3
$4.5M Sell
61,353
-47,706
-44% -$3.35M 0.03% 265
2019
Q2
$6.72M Buy
109,059
+9,165
+9% +$554K 0.04% 196
2019
Q1
$6.37M Sell
99,894
-819
-0.8% -$46.7K 0.04% 200
2018
Q4
$5.14M Buy
100,713
+7,242
+8% +$366K 0.04% 190
2018
Q3
$5.42M Buy
93,471
+15,699
+20% +$768K 0.03% 204
2018
Q2
$3.77M Buy
77,772
+17,346
+29% +$810K 0.02% 272
2018
Q1
$2.81M Sell
60,426
-2,991
-5% -$130K 0.02% 317
2017
Q4
$2.38M Sell
63,417
-2,502
-4% -$91.8K 0.01% 371
2017
Q3
$2.4M Buy
65,919
+657
+1% +$25.1K 0.02% 355
2017
Q2
$2.57M Buy
65,262
+159
+0.2% +$5.8K 0.02% 341
2017
Q1
$2.04M Sell
65,103
-2,457
-4% -$76.9K 0.01% 393
2016
Q4
$2.11M Buy
67,560
+1,050
+2% +$34K 0.02% 377
2016
Q3
$2.67M Sell
66,510
-5,202
-7% -$196K 0.02% 315
2016
Q2
$2.38M Buy
71,712
+909
+1% +$31.1K 0.02% 333
2016
Q1
$2.08M Sell
70,803
-2,994
-4% -$82.6K 0.02% 358
2015
Q4
$1.94M Sell
73,797
-1,095
-1% -$28.4K 0.02% 368
2015
Q3
$1.77M Sell
74,892
-1,296
-2% -$31.3K 0.01% 376
2015
Q2
$1.81M Buy
76,188
+2,178
+3% +$49.2K 0.01% 398
2015
Q1
$1.76M Sell
74,010
-36
-0% -$808 0.01% 407
2014
Q4
$1.57M Sell
74,046
-20,328
-22% -$408K 0.01% 419
2014
Q3
$1.61M Sell
94,374
-870
-0.9% -$13.7K 0.01% 457
2014
Q2
$1.36M Sell
95,244
-3,186
-3% -$43.2K 0.01% 509
2014
Q1
$1.22M Sell
98,430
-1,554
-2% -$17.9K 0.01% 533
2013
Q4
$1.1M Buy
99,984
+2,478
+3% +$27.9K 0.01% 536
2013
Q3
$1.13M Sell
97,506
-1,038
-1% -$12.1K 0.01% 503
2013
Q2
$1.1M Buy
+98,544
New +$1.17M 0.01% 494

Other funds holding EW

CIBC Asset Management's EW Position: Q2 2026 in Review

CIBC Asset Management reduced its Edwards Lifesciences (EW) stake by 2.3% in Q2 2026, selling an estimated $265K and leaving 136,785 shares worth $12.4M. The position accounts for 0.03% of the portfolio, ranked #363.

CIBC Asset Management first reported a position in EW in Q2 2013 and has held it in 53 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • CIBC Asset Management held 136,785 shares of Edwards Lifesciences worth $12.4M as of Q2 2026.
  • CIBC Asset Management sold 3,169 Edwards Lifesciences shares in Q2 2026, an estimated $265K.
  • Edwards Lifesciences made up 0.03% of CIBC Asset Management's portfolio in Q2 2026, its #363 holding.
  • CIBC Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.